Ronald Hoffman

TL;DR: The author examines the immune system through the lens of Epstein-Barr Virus-Associated Diseases, as well as the biology of Stem Cells and Disorders of Hematopoiesis, and the approach to the Adult and Child with Anemia.

TL;DR: This document updates the recommendations on the management of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs), and both recombinant interferon alpha and the JAK1/JAK2 inhibitor ruxolitinib are recommended as second-line therapies for PV patients who are intolerant or have inadequate response to hydroxyurea.

TL;DR: The current document is a revision of the International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria for treatment response in myelofibrosis and represents a collaborative effort by the IWG-MRT and the European LeukemiaNet to objectively assess the value of new drugs in inducing morphologic remission or improvement in MF-associated symptomatic burden.

TL;DR: In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms.

TL;DR: Revised recommendations for assessing response in ET and PV are presented by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment that include new definitions of complete and partial remission that include a standardized symptom assessment form.